Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib before HSCT in Myelofibrosis
NCT01795677Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Dec 2012
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), sponsored by French Innovative Leukemia Organisation. Started Dec 2012; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01795677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01795677.